Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The State of the Muscular Dystrophy Drug Pipeline

By Drug Discovery Trends Editor | February 26, 2016

The path to marketing an effective drug for Duchenne muscular dystrophy (DMD) hit another snag earlier this week.

PTC Therapeutics, a drug maker located South Plainfield, NJ, received a Refusal to File letter from the Food and Drug Administration (FDA) for PTC’s DMD candidate Translarna. The document explained PTC’s marketing application needed more information to warrant an in-depth review, according to the company’s press release.

DMD is a rare genetic disorder with no cure that induces gradual muscle loss by inhibiting the growth of a protein called dystrophin. It mostly affects young boys, according to the Muscular Dystrophy Association. The lack of this protein can make it difficult for afflicted individuals to breathe or move after a certain amount of time.

Translarna, along with rival drugs made by Sarepta Therapeutics and BioMarin Pharmaceuticals, are being scrutinized as potential treatments for DMD since the drugs are aimed at producing higher levels of dystrophin, reports STAT.

However, the one thing all of these companies have in common is that they’ve submitted applications with insufficient information in hopes of being the first to market.

FierceBiotech writes that PTC felt it could present a compelling case to the FDA for Translarna’s ability to treat a subpopulation of DMD patients even though the drug failed a Phase 2b study and a Phase 3 study last fall. The drug was unable to prove it could help patients walk better versus a placebo.

Sarepta and BioMarin received similar rejections after an agency advisory panel determined clinical trial data failed to prove these drugs were effective in helping treat DMD.

Research and consulting firm GlobalData released a report last year saying the global Duchenne muscular dystrophy market will be worth $990 million by 2019. Fast clinical development and significant demand for the aforementioned drugs will help propel that growth, the report predicted.

The report’s author stipulates, though, there needs to be better tools for measuring clinical efficacy for DMD patients because there are multiple variants of the disorder, and the common method of using a six-minute walk test as the primary clinical endpoint is not reliable.

It’s unknown how these developments will impact the DMD pipeline going forward, but early research suggests the controversial gene-editing technique, Crispr-Cas9, could be a viable alternative. 

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community! Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE